2型糖尿病管理：每周一次联合治疗时代来临？
本文回顾了糖尿病治疗的发展历程，从1921年动物源胰岛素的分离到重组人胰岛素和类似物的开发，再到超长效胰岛素简化给药方案的出现。文章指出2型糖尿病治疗的重要进展还包括GLP-1受体激动剂的问世，这类药物具有有效控制血糖、减轻体重和低血糖风险低的优势。
要点
- 超长效胰岛素可简化给药方案
- GLP-1受体激动剂具有有效控制血糖、减轻体重和低血糖风险低三重优势
- 糖尿病治疗从1921年动物源胰岛素发展至今已历经多次变革
核心结论
- 2型糖尿病治疗已从早期胰岛素发展到超长效胰岛素和GLP-1受体激动剂等新型治疗方式
主要发现
- GLP-1受体激动剂可有效控制血糖、减轻体重且低血糖风险低
临床怎么用
- 超长效胰岛素可简化给药方案
- GLP-1受体激动剂适用于需要控制血糖、减重且希望降低低血糖风险的2型糖尿病患者
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
The isolation of animal-derived insulin in 1921 heralded a revolution in diabetes management, lifesaving for many and health preserving for many more. Further progress in purity and duration of action was followed by development of recombinant human insulin and analogues designed to more closely mimic normal physiology and reduce side effects.1 More recently, there has been a focus on ultra-long-acting insulins with simplified dosing schedules.2 Other important developments in type 2 diabetes include the advent of GLP-1 receptor agonists, which have the benefits of efficacious glycaemic control, weight reduction and low risk of hypoglycaemia.
引用
- The Lancet Diabetes and Endocrinology：[Comment] Type 2 diabetes management: weekly combination therapy comes of age?
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。